Thursday, August 31, 2023
As communicated on the 18th of October 2022, Gamma Gurus and ChemoTech have been having discussions regarding an expansion of the cooperation to include the IQwave™ device for Tumour Specific Electroporation™ (TSE) to the human care market in Australia. Today this agreement has been signed by both parties.
With cancer emerging as the leading cause of death in Australia, the country is actively investing in advanced research and treatments for diverse cancer types1, 2. The country's robust healthcare infrastructure, well-regulated clinical trials, and patient-centric approach contribute to its forefront position in delivering comprehensive and innovative cancer care.
TSE holds substantial potential for personalized treatment of both superficial and deep solid tumours, particularly when integrated with chemotherapy, immunotherapy, and radiotherapy.
“Despite its geographical distance from Europe and India, Australia remains a pivotal market due to its substantial skin cancer prevalence and valuable clinical research prospects. Our goal is to establish both commercial avenues and academic collaborations to advance TSE for solid tumours, utilizing inventive trial frameworks that integrate TSE with immunotherapy and radiotherapy for both curative and palliative contexts”, says Dr Suhail Medical Director at Scandinavian ChemoTech.
“Gamma Gurus is delighted to offer access to IQwave and its TSE technology within our designated territories, providing valuable solutions to the human cancer care market. The potential of TSE in addressing various treatment gaps in solid tumor therapy is noteworthy, and the upcoming clinical trials hold the promise of enhancing its applicability in Australian cancer care”, says Jason Beirne, Managing Guru at Gamma Gurus.
"Expanding operations in Australia alongside Gamma Gurus, in a highly strategic market, is very exiting. Our distributor agreement with Gamma Gurus signifies a promising debut in the Australian and nearby markets, opening doors for advanced TSE treatments and clinical trials", says Mohan Frick, CEO of Scandinavian ChemoTech.
About Gamma Gurus Pty Ltd
Gamma Gurus brings over 100 years of experience in diagnostic imaging, radiation therapy, and radioactive material management together in one place. Their goal is to provide unsurpassed solutions and services to their customers with a professional and hassle-free attitude. Their extensive network ensures that they will be able to source the best products from around the world to meet the needs of the local healthcare community. Their decades of local knowledge guarantee that suppliers and customers alike have the support to navigate the complex regulatory, logistics, and technical nuances of the local markets.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.
Source: chemotech.se
